Mucins carrying selectin ligands as predictive biomarkers of disseminated intravascular coagulation complication in ARDS

Chest

Volumn 139, Issue 2, 2011, Pages 296-304

  Nakashima, Taku ^a   Yokoyama, Akihito ^b   Inata, Jyunya ^a   Ishikawa, Nobuhisa ^a   Haruta, Yoshinori ^a   Hattori, Noboru ^a   Kohno, Nobuoki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP ANTIGEN; MUCIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; SELECTIN; SIALYL LEWIS A; SIALYL LEWIS X ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

EID: 79551578219     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-3082     Document Type: Article

References (37)

1. Rubenfeld GD, Herridge MS. Epidemiology and outcomes of acute lung injury. Chest. 2007;131(2):554-562. (Pubitemid 46280419)
2. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis:novel opportunities for pharmacological intervention? Br J Pharmacol. 2008;153(Suppl 1): S367-S378.
3. Ware LB, Camerer E, Welty-Wolf K, Schultz MJ, Matthay MA. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2006; 291(3):L307-L311. (Pubitemid 44343703)
4. Matthay MA. Treatment of acute lung injury:clinical and experimental studies. Proc Am Thorac Soc. 2008;5(3):297-299. (Pubitemid 351520675)
5. Steinberg KP, Hudson LD, Goodman RB, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome(ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16):1671-1684.
6. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest. 2009; 136(6):1631-1643.
7. Bajwa EK, Khan UA, Januzzi JL, Gong MN, Thompson BT, Christiani DC. Plasma C-reactive protein levels are associated with improved outcome in ARDS. Chest. 2009;136(2): 471-480.
8. Wu J, Sheng L, Wang S, et al. Analysis of clinical risk factors associated with the prognosis of severe multiple-trauma patients with acute lung injury. J Emerg Med. In press. doi: 10.1016/j.jemermed.2009.05.024.
9. Gando S, Kameue T, Matsuda N, Sawamura A, Hayakawa M, Kato H. Systemic inflammation and disseminated intravascular coagulation in early stage of ALI and ARDS: role of neutrophil and endothelial activation. Inflammation. 2004; 28(4):237-244. (Pubitemid 41449424)
10. Nakashima T, Yokoyama A, Ohnishi H, et al. Circulating KL-6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome. J Intern Med. 2008;263(4):432-439. (Pubitemid 351342685)
11. Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004;32(12):2416-2421. (Pubitemid 39648222)
12. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2(11):1924-1933.
13. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35(9):2191-2195.
14. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med. 2008;178(6):618-623.
15. Wada H, Wakita Y, Nakase T, et al; Mie DIC Study Group. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemost. 1995;74(3):848-852.
16. Norman KE, Cotter MJ, Stewart JB, et al. Combined anticoagulant and antiselectin treatments prevent lethal intravascular coagulation. Blood. 2003;101(3):921-928.
17. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest. 2006;116(12):3211-3219. (Pubitemid 44878635)
18. Donnelly SC, Haslett C, Dransfield I, et al. Role of selectins in development of adult respiratory distress syndrome. Lancet. 1994;344(8917):215- 219. (Pubitemid 24229007)
19. Stengel D, Bauwens K, Keh D, et al. Prognostic value of an early soluble L-selectin (sCD62L) assay for risk assessment in blunt multiple trauma:a metaanalysis. Clin Chem. 2005; 51(1):16-24. (Pubitemid 40024008)
20. Varki A. Trousseau's syndrome:multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723-1729. (Pubitemid 47443881)
21. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectinmucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112(6):853-862. (Pubitemid 38063743)
22. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989; 96(1):68-73.
23. Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148(3): 637-642. (Pubitemid 23263772)
24. Yokoyama A, Kohno N, Hamada H, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158(5 Pt 1): 1680-1684.
25. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002; 165(3):378-381. (Pubitemid 34118512)
26. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006;11(2):164-168.
27. Ishizaka A, Matsuda T, Albertine KH, et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol. 2004;286(6):L1088-L1094.
28. Sato H, Callister ME, Mumby S, et al. KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome. Eur Respir J. 2004;23(1):142-145. (Pubitemid 38088511)
29. Ishikawa N, Hattori N, Yokoyama A, et al. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Cancer. 2008;122(11): 2612-2620. (Pubitemid 351590499)
30. Inata J, Hattori N, Yokoyama A, et al. Circulating KL-6/MUC1 mucin carrying sialyl Lewisa oligosaccharide is an independent prognostic factor in patients with lung adenocarcinoma. Int J Cancer. 2007;120(12):2643-2649. (Pubitemid 46651286)
31. Bernard GR, Artigas A, Brigham KL, et al. The American- European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818-824.
32. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327-1330.
33. Hatada T, Wada H, Nobori T, et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 2005;94(5): 975-979. (Pubitemid 41645937)
34. Nathani N, Perkins GD, Tunnicliffe W, Murphy N, Manji M, Thickett DR. Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome. Crit Care. 2008;12(1):R12. (Pubitemid 351437047)
35. Kneuer C, Ehrhardt C, Radomski MW, Bakowsky U. Selectins - potential pharmacological targets? Drug Discov Today. 2006;11(21-22):1034-1040.
36. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004;92(3):459-466. (Pubitemid 39248002)
37. Schleiffenbaum B, Spertini O, Tedder TF. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol. 1992;119(1):229-238.